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Background: In primary health care systems where member’s turnover is relatively low, the question, whether
investment in quality of care improvement can make a business case, or is cost effective, has not been fully answered.
The objectives of this study were: (1) to investigate the relationship between improvement in selected measures of
diabetes (type 2) care and patients’ health outcomes; and (2) to estimate the association between improvement in
performance and direct medical costs.
Methods: A time series study with three quality indicators – Hemoglobin A1c (HbA1c) testing, HbA1C and
LDL- cholesterol (LDL-C) control - which were analyzed in patients with diabetes, insured by a large health fund.
Health outcomes measures used: hospitalization days, Emergency Department (ED) visits and mortality. Poisson,
GEE and Cox regression models were employed. Covariates: age, gender and socio-economic rank.
Results: 96,553 adult (age >18) patients with diabetes were analyzed. The performance of the study indicators,
significantly and steadily improved during the study period (2003–2009). Poor HbA1C (>9%) and inappropriate
LDL-C control (>100 mg/dl) were significantly associated with number of hospitalization days. ED visits did not
achieve statistical significance. Improvement in HbA1C control was associated with an annual average of 2%
reduction in hospitalization days, leading to substantial reduction in tertiary costs. The Hazard ratio for mortality,
associated with poor HbA1C and LDL-C, control was 1.78 and 1.17, respectively.
Conclusion: Our study demonstrates the effect of continuous improvement in quality care indicators, on health
outcomes and resource utilization, among patients with diabetes. These findings support the business case for
quality, especially in healthcare systems with relatively low enrollee turnover, where providers, in the long term,
could “harvest” their investments in improving quality.Background
During the last two decades, the quality of care has drawn
increasing attention of health care systems. Among the
cornerstones shaping this interest, were the inception
of the Healthcare Effectiveness Data and Information Set
(HEDIS) tool, which became available in 1993, with an-
nual reporting of community-based performance mea-
sures of 90% of US health plans [1]; a series of articles on
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article, unless otherwise stated.Journal of Medicine in 1996, illustrated how changes in
measurement and quality improvement may affect physi-
cians and patients over the coming decade [2]; and the
2001 Institute of Medicine (IOM) report, claiming that
the US healthcare system needs to be re-designed in order
to cross the “quality chasm” [3].
The term “Business Case” has been used to convince de-
cision makers to invest in short-term actions which could
lead to substantial benefits in the long term period of
time. However, the lack of return on investments within a
reasonable time period, has been an obstacle to making a
business case for improving health care quality [4].tral Ltd. This is an Open Access article distributed under the terms of the
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, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Wilf-Miron et al. BMC Endocrine Disorders 2014, 14:92 Page 2 of 7
http://www.biomedcentral.com/1472-6823/14/92System-wide reengineering of care in the American
Veterans Affairs (VA) healthcare system has resulted
in significant improvements in diabetes care indicators
[5,6]. In 2004, the British Government introduced a
pay-for-performance and quality monitoring scheme with
136 indicators for family practices. The indicators covered
management of chronic disease, practice organization,
and patients’ experiences with respect to care [7]. This
scheme was associated with improvements in recorded
quality of diabetes care in the first year; modest im-
provements in subsequent years; and with variation in
care between population groups which diminished
under the incentives, but remained substantial in some
cases [8].
The Israeli National Quality Measurement Program
(IOM) [9] has demonstrated substantial improvements
in most diabetes care indicators during the past years,
compared with those of the American HEDIS [10,11].
Numerous studies have shown the effect of organizational
or local efforts on performance indicators; however, fewer
studies have looked at the effect of improvement in per-
formance indicators on improvement in either patients’
health outcomes [12,13] or medical costs. A recent publica-
tion by the IOM claims that the US healthcare system had
become too complex and costly to maintain business as
usual. The report suggests that transformational changes
are required to shape a health care system which delivers
the best care at the lowest cost [14].
Maccabi Healthcare Services (MHS) is the second
largest Israeli health plan, providing community-based
health services to two million members throughout the
country. Service is delivered and managed by five re-
gions through 150 branches. MHS, like other Israeli
health plans, enjoys fully computerized health records.
As a provider of community-based primary and second-
ary health care, MHS contracts with local hospitals to
purchase tertiary care. The cost of hospitalization ser-
vices is the single largest component in the MHS’ budget
(41.2% of its expenses in 2009).
In 2004, MHS implemented a “Performance Measure-
ment System” (PMS), which helped focus the organiza-
tion’s attention on selected clinical domains, including
diabetes care. To encourage care improvement, annual
targets were set for all units, with modest rewards given
to units achieving their targets. Additionally, MHS has
developed quality infrastructures at the central and re-
gional levels to encourage adoption of quality concepts
and tools and allow for organizational learning from suc-
cess and failure.
Diabetes, which is a major chronic disease, is one of
the clinical domains which has attracted intense MHS
effort to improve the care provided to its members
[15,16]. As evidence, 5 of the 24 indicators monitored by
MHS’ PMS are related to diabetes care.The objectives of this study were: (1) to investigate
the relationship between improvement in selected measures
of diabetes (type 2) care and patients’ health outcomes; and
(2) to estimate the effect of improved performance on dir-
ect medical costs.Methods
Study design
Time series study with repeated measurements.Setting
The study was conducted by MHS, using retrospective
data for the period 2003–2009.Focus of analysis
Two intermediate outcome (HbA1C and LDL-Cholesterol
control among patients with type 2 diabetes) and one
process (HbA1C testing) measures were analyzed. Indicator
selection was based on availability of complete longitudinal
data and “stable” definitions (i.e., measure definition did not
change during the period covered by the data). Health out-
comes were represented by number of hospitalization days,
Emergency Department (ED) visits and mortality.Study population
All MHS members aged 18 and above listed in the MHS
Diabetes Registry (DR), between 2003 and 2009 [17].
Mean time of follow up was 8.5 (±1.7) years.Data source
HbA1C and LDL cholesterol (LDL-C) test results and
documentation of HbA1C testing were retrieved from
the MHS PMS. Number of hospitalization days and ED
visits (per patient, per year), time of death (date), age,
gender and socio-economic rank (SER) were retrieved
from the MHS central databank.Quality indicator definitions
HbA1C testing: Documented at least once during the
measurement year; poor Glycemic control: HbA1C > 9%
in the last recorded test for each year; LDL-C control:
LDL-C < 100 mg/dl in the last recorded test for each
year. All indicators were based on the American HEDIS
definitions [1].Other definitions
SER
The socio-economic rank of the member’s residential
neighborhood for the period studied, measured on a 10-
point scale, were retrieved from the census data kept by
the Israel Central Bureau of Statistics [18].
Table 1 Study population characteristics
Variable N = 96,553





No available data 5.9
Mean time of follow up 8.5 (±1.7) years
*SER: Socio-Economic Rank.
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Linear regression models were employed in order to
evaluate the change in performance of selected indica-
tors between the years 2003 and 2009.
Repeated measurement data set structure
The data set comprised for each DR registered patient
all the information under investigation, for each year
(2003–2009 = 7 lines 2009–2012 death information =
additional 3 lines).
Poisson regression models were employed in order to
account for the prevalence of zero counts in the data.
The zero-inflated (or zero-altered) Poisson model allows
over dispersion, through the splitting process, that
models the outcomes as zero or nonzero.
Additionally, Generalized Estimating Equations (GEEs)
were employed. GEEs fit generalized linear models of
the dependent variable yit (in our case: hospital days)
with covariates xit.
g E yitð Þf g ¼ xitβ; yeF with parameters θit
for i = 1,…,m and t = 1,…, ni, where there are ni obser-
vations for each group identifier i (in our case, the pa-
tient’s ID). g( ) is called the link function, and F is the
distributional family. Substituting various definitions for
g( ) and F result in a wide array of models. In our case,
yit is assumed to be distributed negative binomial and g( )
is log, therefore:
log E yitð Þf g ¼ xitβ; yenegative binomial with parameter k ¼ 1
yielding log-linear regression related models, depending
on what is assumed for the within-group (within the par-
ticular patient’s records, in our case) correlation structure.
Let R be the working correlation matrix for modeling
the within-group correlation, a square max{ni} ×max{ni}
matrix. Let Rt,s denote the t, s element. We assumed that
the working correlation matrix is independent, therefore:
Rt;s ¼ 1; jt ¼ s0; t≠sj

Using GEEs with the independent correlation matrix
corresponds to exploiting cluster option in General Lin-
ear Models (in our case, cluster is a set of the particular
patient’s records).
The global model takes the “time” as a reference point,
while the dynamic model takes the variations in “time”
along the study period. Global models were employed
for hospitalization days and death. Dynamic models were
employed for hospitalization days.
To evaluate association between the study year and
HbA1C levels, the interaction variable “HbA1C_year”
was computed by multiplying HbA1c indicator (i.e., the
binary, 0-or-1, variable that equals 1 if HbA1c is greaterthan the fixed at the particular year level of HbA1c) by
the sequel year (starting with 0 as the year of entering
into the study and going up with follow-up years).
To estimate the effect on death, a Cox Regression
model was employed. This model fits the hazard, assum-
ing an exponential function of the summation of the re-
gression coefficients b1,…,bk. The Cox model provides
estimates of b1,…,bk but provides no direct estimate of
the baseline hazard. For this task, data on death events
were retrieved from MHS’ central warehouse, and the
years 2010–2012 were added.
To estimate average proportion of annual reduction in
hospitalization days (saving days), the coefficient of dy-
namic model minus the coefficient of global model was
calculated. To calculate cost savings, the number of
hospitalization days saved was multiplied by cost per
hospitalization day as noted on the Israeli Ministry of
Health price list [19]. This price list is based on an aver-
age of direct cost between the internal and other general
wards and corrected to the year of data analysis.
All models were adjusted for age, gender and SER con-
sidered as potential confounders. To analyze the data,
STATA ver. 12 and SPSS ver.20 software were used.
Alpha level for statistical significance was 0.05.
Results
The analysis included data collected on 96,553 registered
adult patients with diabetes. Mean age was 64.3 (±13.9),
43.5% were females and 64.7% belonged to the higher
SERs (ranks 6–10) (Table 1).
During 2003–2009, rates of HbA1C testing increased
from 43.8% to 69.6%; rates of HbA1C poor control de-
creased from 13% to 9.2%, and rates of LDL-C control
increased from 29.4% to 57.7% - all statistically signifi-
cant (Table 2).
The Poisson model for hospitalization days (as the
depended variable), revealed a significant association
(P < 0.0001) with poor HbA1C and LDL control (Table 3).
Both the global and dynamic GEE models revealed a
positive and significant association between poor HbA1C
control (>9%), lack of LDL-C control (>100 mg/dl) and
number of hospitalization days (Table 4).
Table 2 Performance rates (%) of selected indicators, 2003-2009
Indicator 2003 2004 2005 2006 2007 2008 2009 P value*
HbA1C > 9% NM† 13.0 11.1 11.7 11.1 9.3 9.2 0.010
LDL Control <100 mg/dl 29.4 30.9 37.7 47.2 50.5 56.7 57.7 <0.001
HbA1C testing 43.8 49.5 54.5 59.0 62.3 64.8 69.6 <0.001
*linear regression models; †Not measured.
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proportion of patients with poor HbA1C and LDL con-
trol consistently and significantly decreased each year
(Table 4). HbA1C testing did not reach statistical
significance and was thus removed from further models
(P = 0.785).
The models for ED visits as a dependent variable were
too weak (LR Chi2 = 73.4) to demonstrate any associ-
ation with the independent variables.
Death as a dependent variable was positively and signifi-
cantly associated with the following indicators: poor HbA1C
control and inappropriate LDL-C control (>100 mg/dl). The
hazard ratio for time of death (as a dependent variable) for
HbA1C> 9% and LDL-C > 100 mg/dl indicators was 1.78
and 1.17 (P < 0.001), respectively (Table 5).
Calculation of the average annual drop in the proportion
of patients with HbA1C > 9% (0.52-0.50) revealed an aver-
age annual saving of 2% in hospitalization days, and a
meaningful saving in hospitalization costs (Table 6).Discussion
Key findings
Our study has demonstrated that over a 6-year-period,
improvement in glycemic and cholesterol control was
associated with significant decreases in hospitalization
days, mortality and direct medical costs. ED visits failed
to demonstrate a similar association.Table 4 Results of three GEE models for hospitalization
days and mortality (dependent variables) adjusted for
age, gender and SER
Variable Coefficient S.E. 95% CI P value
Global ModelHospitalization days
HbA1C >9% 5.35 0.63 4.1-6.6 <0.001
HbA1C > 9%*Year −0.50 0.07 −0.64- −0.35 <0.001
LDL >100 mg/dl 0.13 0.05 0.02-0.24 0.020Results in context
These results may be explained by the fact that im-
proved glycemic and cholesterol control were important
elements in the organization’s efforts to improve quality
of care, through multidisciplinary health promotion pro-
grams created within the framework of a performance
monitoring system that implemented the organization’s
“call for action” [16].Table 3 Results of Poisson regression models for
hospitalization days (dependent variable), adjusted for
age, gender and SER
Variable Coefficient S.E. 95% CI* P value
Hospitalization days
HbA1C >9% −0.059 0.015 −0.089- −0.028 <0.001
LDL >100 mg/dl 0.034 0.002 0.029-0.040 <0.001
*95% confidence interval; S.E = Standard Error.In the early 1990s, the Institute of Medicine (IOM)
[20,21] defined quality as the “degree to which health
services for individuals and populations increase the
likelihood of desired health outcomes and are consistent
with current professional knowledge”. Quality of care
can then be evaluated on the basis of structure, process,
or outcome [22]. When used appropriately, both process
and outcome measures can provide valid information
about quality objectives [23].
The decision to choose hospitalizations, ED visits and
mortality as health outcomes (the dependent variables)
was based on data availability. Data on diabetes compli-
cations and long-term trends in diabetic patient satisfac-
tion remain unavailable. It has been long claimed that
the use of outcome measures is insufficient for quality of
care assessment since most differences between patients
receiving the same treatment result from factors associ-
ated with patients’ characteristics – which are outside
the control of health care providers [23]. Following our
experience [24], it is believed that beyond the differences
in personal characteristics, differences in care provided
to MHS members tend to be marginal. However, differ-
ences in personal characteristics (gender, age and socio-
economic rank) were adjusted in all the statistical models.
It is suggested that further research will be conducted with
a control for patient characteristics such as self-efficacy,Mortality
HbA1C >9% 0.55 0.04 0.45-0.64 <0.001
LDL >100 mg/dl 0.20 0.03 0.14-0.27 <0.001
Dynamic ModelHospitalization days
HbA1C >9% 5.75 0.67 4.2-6.8 <0.001
HbA1C >9% *Year −0.52 0.07 −0.67- −0.36 <0.001
LDL >100 mg/dl 0.13 0.05 0.018-0.24 0.022
*95% confidence interval.
Table 5 Cox regression model for time to death (dependent
variable), adjusted for age, gender and SER (2003–2012)
Variable Hazard ratio S.E 95% CI† P value
HbA1C > 9% 1.78 0.08 1.63-1.95 <0.001
LDL > 100 mg/dl 1.17 0.039 1.09-1.25 <0.001
Notes: †95% Confidence Interval.
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medical regiment, and so forth.
Data obtained from the Israeli National Program for
Quality Indicators (NPQI) in Community Healthcare [9]
indicated a 0.25% annual increase in diabetes prevalence
from 2004 to 2010. National census data indicated that
diabetes-related mortality rates, adjusted for ethnicity
and gender, have decreased by 24% from 2004 to 2010
[25], most probably due to better control of intermediate
outcome measures and better care for diabetes compli-
cations. Although data on diabetes-related hospitaliza-
tions are not available, crude national figures indicate a
steady increase in hospitalization days between 2000 and
2010 [26].
It is worth mentioning that the NPQI, instituted in
2004, contributed to each of the four Israeli health plans,
including MHS, for development of quality improving
infrastructures, which resulted in improved performance
indicators in most measured domains. It is, therefore,
suggested that the observed continuous improvement in
the selected measures presented here is not exclusively
the result of “natural improvement”.
MHS’ performance monitoring system was a necessary
but insufficient element for the explanation of long-term
care improvement. Regional “Quality Teams”, comprised
of physicians, nurses and other health professionals in
managerial positions, were set up and trained to guide
analysis of quality gaps and implementation of effective
interventions. Resources were allocated to intervene in
units which had exhibited wide gaps between actualTable 6 Saving of hospitalization days due to improvement
in HbA1C > 9% indicator 2005–2012
Year Hospital days Saving Saving in NIS*
2005* 94,447 1,927 3,944,000
2006 137,325 2,802 5,604,000
2007 176,131 3,594 7,188,000
2008 200,487 4,091 8,182,000
2009 195,606 3,991 7,982,000
2010 219,813 4,485 8,970,000
2011 205,563 4,195 8,390,000
2012 110,851 2,262 4,524,000
1NIS (Israeli Shekel) = 3.6 US$.
Note: *Since measurement and systemic quality improvement efforts were
initiated in 2004, we calculated the decrease in hospitalizations as result in
improved diabetes control from 2005. The effect of improved control in 2009
is expected to have an effect on hospitalization at least until 2012.performance and desired targets. Considerable effort has
been invested in empowering patients throughout pro-
grams to increase treatment adherence [27], among
other steps taken [16].
Our study also demonstrated association between sig-
nificant reduction in mortality and improved glycemic
and cholesterol control. Data from the United Kingdom
has shown that the mortality risk among patients with
Type 2 Diabetes is 1.6 times higher than that of the gen-
eral population [28]. Landman and colleagues have re-
ported that patients with diabetes evidencing poor
glycemic control (HbA1C > 9%) exhibited a hazard ratio
of 2.21 for total mortality, compared with a hazard ratio
of 1.0 among the control group with normal glycemic
control levels (HbA1C < 6.5%). This suggests that in
order to increase life expectancy, interventions should
focus mainly on patients evidencing poor control [29].
The literature also shows that correction of dyslipidemia
(such as control of LDL-C) in patients with diabetes pro-
motes reduction of macro-vascular disease, which con-
tributes to cardio-vascular complications and shortened
life span [30].
The models for ED visits (as a dependent variable) cal-
culated in this study were too weak to produce significant
statistical results. HbA1C performance (as an independent
variable) was not found to be associated with either
hospitalization days or death. It seems logical that this
process variable is insufficiently powerful to explain these
two outcomes. Additionally, HbA1C is measured as per-
formed at least once a year; the findings indicate that test-
ing only once a year is insufficient for disease control and
achievement of desired outcomes.
Providing appropriate care for patients with diabetes,
especially those exhibiting complications resulting from
poor disease control, demands considerable resources.
Improving the quality of care to patients with diabetes
and achieving better health outcomes is also costly
[15,31-33]. Moreover, health care systems around the
world are facing pressure to constrain costs, given the
rise in medical sophisticated technologies and the aging
of the population, among other reasons. Those trends
prompt health care organizations’ decision makers to ex-
pect a “business case” for quality improvement, meaning
that these investments would have a “return on invest-
ment” (ROI) within a reasonable period of time. The an-
nual average result of 2% reduction in hospitalization
days through the reduction in poor glycemic control is a
preliminary pivotal evidence for such a business case.
The results comply with the results of several other
studies [34-38], whose authors conclude that sustained
reduction in HbA1C levels among patients with diabetes
is associated with significant cost savings within 1–2
years of level reduction. MHS, as all other Israeli HMOs,
is characterized by a very low patient turn over, meaning
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HMO during its life time. This fact urges the Israeli
HMOs to invest in quality improvement, knowing that
they can return their investments in the long term.
Blumenthal and colleague [4] argue that a leading obs-
tacle to achieving quality in health care is the absence of
a “business case” for quality. Healthcare system infra-
structure is frequently accused of being inadequate to
support such thinking. Furthermore, one of the root
causes mentioned is the primitive quality measurement
stage of science; if most healthcare providers are unable
to estimate the total cost of investing in quality, how can
one expect them to calculate the savings produced by
their investment in interventions? Also, interventions to
improve diabetes care produce return on investment
only in the medium- to long-term (delayed savings).
Therefore, healthcare organizations with a high turnover
may not be able to achieve this return [39]. In times of aus-
terity, the majority of budget cuts take place in the health-
care sector [40], which adds pressure on organizations to
economically “justify” quality improvement investments.
Study’s strengths and limitations
The strength of this study lies in the fact that data were
analyzed for a very large study population (N = 96,553)
comprising all adult members of a major health plan,
registered in the Diabetes Register, which increases the
statistical validity of the findings. In addition, a robust
statistical techniques were employed to support the hy-
pothesized results.
Yet, the study has considerable limitations, which
should be overcome in future studies: (1) The effect of
only three diabetes performance measures was studied.
Appropriate follow up with process measures such as
eye and foot examinations or medical attention for ne-
phropathy as well as intermediate blood pressure control
were not included in the analysis because the measure’s
definition changed during the study period or the meas-
ure was not documented throughout the study period;
(2) our information system, although fully computerized,
was not designed to collect accurate and full data on the
costs of quality improvement interventions or medical
expenditures directly related to diabetes care; hence, the
“investment” side of the “business case” argument was
not thoroughly looked at. The data cannot be appropri-
ately used to substantiate returns on investments in
quality. Furthermore, the cost of hospitalization is sub-
ject to local agreements and contracts between HMOs
and hospitals, and is not publicly transparent. The esti-
mated cost saving is, therefore, based on the price list
published by Israel’s Ministry of Health, which may not
fully reflect actual prices. 3). This study investigated the
entire MHS’ population; thus, a control group was not
available, as all MHS members were under the qualityimprovement scheme. A further investigation with a case
control design is recommended.
Conclusion
In conclusion, our study indicates the effect of continu-
ous improvement in performance indicators on health
outcomes and resource utilization among patients with
diabetes. In health care systems with relatively low mem-
ber turnover and beneficiaries who do not leave their
HMO for a long period of time, this finding represents
an important milestone, linking quality and cost, helping
to construct the business case approach to quality; these
conclusions may convince managers to invest scarce re-
sources in care improvement.
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